One-year clinical outcomes of patients implanted with a Resolute Onyx™ zotarolimus-eluting stent. Issue 1 (January 2018)

• Record Type: Journal Article
• Authors: Tam, Chor Cheung; Chan, Kelvin; Lam, Simon; Yung, Arthur; Lam, Yui Ming; Chan, Carmen; Siu, David; Tse, Hung Fat
• Is Part Of: Journal of international medical research. Volume 46:Issue 1(2018)
• Page Start: 457
• Page End: 463
• Publication Date: 2018-01
• Subjects: Drug-eluting stent -- zotarolimus-eluting stent -- coronary artery disease; Medicine -- Periodicals; Pharmacology -- Periodicals; 610.5
• DOI: 10.1177/0300060517717826
• Languages: English
• ISSNs: 0300-0605

Abstract

Objective: To evaluate the 1-year clinical outcomes of patients who received the Resolute Onyx™ stent. Methods: This was a single-centre, retrospective registry analysis that reviewed the clinical data from all patients who were implanted with a Resolute Onyx™ stent between March 2015 and February 2016. Clinical follow-up was performed at 1 year post-implantation. Results: A total of 252 patients received a Resolute Onyx™ stent and two patients were lost to follow-up. The mean age of the cohort was 66.9 years and 113 (45.2%) had diabetes mellitus. Thirty-eight patients (15.2%) had left main disease and 73 (29.2%) had three-vessel disease. A total of 175 patients (70.0%) had small vessel disease (<2.75 mm) and 210 (84.0%) had long lesions (>20 mm). The 1-year target lesion failure was 4.4% (11 of 250), cardiovascular death occurred in eight patients (3.2%), ischaemia-driven target lesion revascularization was undertaken in five patients (2.0%) and stent thrombosis occurred in one patient (0.4%). Conclusion: The Resolute Onyx™ stent showed a favourable 1-year clinical performance in a real-world population.